Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133227 | 1.00 | CYP19A1 (0.41) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| SCHEMBL13059722 | 1.00 | CYP19A1 (0.41) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| SCHEMBL5556172 | 0.80 | GLA (0.30) | HPGD | |
| SCHEMBL16015689 | 0.80 | CYP19A1 (0.48) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| SCHEMBL24249845 | 0.78 | CYP19A1 (0.53) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| SCHEMBL13557795 | 0.78 | CYP19A1 (0.53) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| SCHEMBL18381170 | 0.77 | CYP19A1 (0.46) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| Triethyl Citrate SCHEMBL1951148 | 0.74 | TRPM8 (0.51) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| Triethyl Citrate SCHEMBL1951146 | 0.74 | TRPM8 (0.51) | CYP19A1EPHX1MAPTNPSR1TSHR | |
| SCHEMBL18585987 | 0.73 | CYP19A1 (0.50) | CYP19A1EPHX1MAPTNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1064285-B1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | STRAGEN PHARMA SA (CH) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | CYP19A1 767/4885EPHX1 306/4885MAPT 840/4885 |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | CYP19A1 767/4885EPHX1 306/4885MAPT 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.